By the end of 2022, the global market will be worth US$ 16.9 billion, and it will grow at a CAGR of 6.2% to be worth US$ 32.6 billion by 2033. According to a recent Future Market Insights study, polymers packaging materials are expected to account for 88.3% of the global market in 2023.
In 2022, the market value was approximately 23.5% of the overall US$ 71.9 Bn global nasal drug delivery technology market. From 2015 to 2022, the market expanded at a CAGR of 5.8%.
Also, growing equipment approvals by regulatory bodies are expected to benefit the market in the forecast period. For instance, in March 2019, FDA approved Spravato nasal spray for curing adult patients with treatment-resistant depression. In 2018, FDA revealed that about 7.4 million adults suffer from treatment-resistant depression in the U.S which widens the scope of suicidal tendencies and hospitalizations. The nasal spray offers drugs in an easy way since it comprises active ingredients and medications which are dissolved in solutions.
Request a Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-13112
Players in the market are taking various initiatives to develop the market in the forecast period. Increasing investment in R&D to offer innovative products in the market is likely to prepare a conducive environment for market growth during the forecast period. For instance, in February 2022, Glenmark Pharmaceuticals Ltd., a renowned pharmaceutical company, and Canadian pharmaceutical company SaNOtize Research & Development Corp announced the launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray ® in India. The product aims to kill the COVID-19 virus in the upper airways. Such initiatives are expected to augment the market size in the assessment period.
However, nasal may spray result in itchiness, redness, and swelling in the nose, leading to reduced consumption, thus, hindering the market expansion. Further, the regulatory obstructions owing to strict laws for the sales of drugs in countries such as Russia and Mexico are likely to be another potential factor controlling the market growth. For instance, the regulatory authority of Mexico, COFEPRIS, set forth new guidelines for permitting registrations of generic drugs, which is not inclusive of patents of new therapeutic uses in its linkage system
Key Takeaways from the Market Study:
- The global nasal spray market is expected to secure a market value worth US$ 3.2 Billion in 2022.
- The nasal spray market in Europe is expected to display a CAGR of 5.8% during the forecast period.
- In 2021, the retail segment is expected to have captured about 54% of the global nasal spray market.
- The nasal spray market in North America is expected to display a CAGR of 6% during the forecast period.
Manufacturers are focusing on introducing nasal sprays capable of administering drug formulations with high efficacy and potency. Hence, the introduction of robust product lines has become a reality, leading to a host of new product launches and innovations, remarks an analyst at FMI.
Contact our Market Research Specialist@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-13112
Competition Analysis:
Key players in the global nasal spray market include Astra Zeneca Plc., Cipla Ltd., Johnson & Johnson Services, Inc. (Johnson & Johnson Pacific Pty Limited), Glaxosmithkline Plc., Novartis International AG, Procter & Gamble, Sanofi S.A. (Sanofi-aventis LLC.), Boehringer Ingelheim GmbH, AdvaCare Pharma, Bayer AG (Bayer Consumer Health, Covis Pharma S.a.r.l., Nipro Corporation (NIPRO JMI Pharma Ltd.), Viatris Inc. (Meda Pharmaceuticals Inc.), Perrigo Company plc, AptarGroup, Inc., Berry Global, Inc., URSATEC GmbH, Gerresheimer AG, Bona, Avantor, VWR International, LLC, Spectrum Laboratory Products, Inc. (Spectrum Pharmacy Products), SKS Bottle & Packaging, Inc., and Coster Tecnologie Speciali S.p.A.
Recent Updates from the Industry:
- In October 2021, Cipla’s consumer health arm announced an anti-viral nasal spray called Naselin, which contains ‘povidone Iodine’ to protect against coronavirus and respiratory tract infections.
- In August 2021, CDMO Bora Pharmaceuticals Laboratories Inc. announced its partnership with Kyowa Pharmaceuticals Industry Co. Ltd. The initiative aims to manufacture generic products, including nasal sprays, in Japan.
More Valuable Insights:
Future Market Insights, in its new offering, presents an unbiased analysis of the global nasal spray market, presenting a historical analysis from 2017 to 2021 and forecast statistics for the period of 2022-2032.
The study reveals essential insights on the basis of by Product (Decongestant Sprays, Nasal Steroid Sprays, Nasal Antihistamine Sprays, Nasal Cromolyn Sodium Sprays, Nasal Anticholinergic Sprays, Nasal Triamcinolone Sprays) by Formulation (Aqueous, Hydroalcoholic, Nonaqueous-Based Solution, Suspension, Emulsions, Dry Powder/Micro particles), by Packaging (Pressurized Canisters, Pump Bottles), by Distribution Channel (Institutional Sales, Retail Sales), & Region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America).
Buy Complete Report@ https://www.futuremarketinsights.com/checkout/13112
Key Players:
- Astra Zeneca Plc.
- Cipla Ltd.
- Johnson & Johnson Services, Inc. (Johnson & Johnson Pacific Pty Limited)
- Glaxosmithkline Plc.
- Novartis International AG
- Procter & Gamble
- Sanofi S.A. (Sanofi-aventis LLC.)
- Boehringer Ingelheim GmbH
- AdvaCare Pharma
- Bayer AG (Bayer Consumer Health
- Covis Pharma S.a.r.l.
- Nipro Corporation (NIPRO JMI Pharma Ltd.)
- Viatris Inc. (Meda Pharmaceuticals Inc.)
- Perrigo Company plc
Key Segments Profiled in The Nasal Spray Market Report
Product:
- Decongestant Sprays
- Nasal Steroid Sprays
- Nasal Antihistamine Sprays
- Nasal Cromolyn Sodium Sprays
- Nasal Anticholinergic Sprays
- Nasal Triamcinolone Sprays
Formulation:
- Aqueous
- Hydroalcoholic
- Nonaqueous-Based Solution
- Suspension
- Emulsions
- Dry Powder/Micro particles
Packaging:
- Pressurized Canisters
- Pump Bottles
Distribution Channel:
- Institutional Sales
- Hospitals
- Community Clinics
- Specialty Clinics
- Public Health Agencies
- Veterinary Hospitals & Clinics
- Retail Sales
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacy
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
